STAMFORD, Conn., Nov. 17, 2014 /PRNewswire/ -- Purdue Pharma L.P. today announced that Gail Cawkwell, MD, PhD, former Vice President in the Medicines Development Group at Pfizer, has joined the company as Vice President of Medical Affairs.
Purdue Pharma, L.P. logo.
"Gail brings to Purdue strong credentials and broad and relevant skills in all aspects of Medical Affairs, including drug development and regulatory and commercial planning," said Mark Timney, President and CEO of Purdue Pharma. "I'm confident that Gail's experience as a physician leader will help us continue serving our patients and customers."
Gail has more than 13 years of pharmaceutical development and medical affairs experience in multiple disease areas. While at Pfizer she held various medical affairs roles including Vice President of Medical Affairs, and Vice President, Medicine Team Lead for Xeljanz.
"It is an honor to lead the Medical Affairs function at Purdue," said Cawkwell. "I am excited to join a company focused on healthcare system innovation and bringing vital treatment options to patients."
Gail received her MD from McGill University and completed a PhD at University of Cincinnati in the Department of Environmental Health, Division of Biostatistics and Epidemiology. She did a Residency in Pediatrics at Duke and a Fellowship in Pediatric Rheumatology at Cincinnati's Children's Hospital Medical Center. Gail continues to care for children with chronic rheumatic diseases on a volunteer basis at Columbia Presbyterian in New York, where she holds the role of clinical instructor since 2002.
About Purdue Pharma L.P.
Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on chronic pain. Headquartered in Stamford, CT, Purdue is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products. Additional information about Purdue can be found at www.purduepharma.com.
Logo - http://photos.prnewswire.com/prnh/20100921/NY67262
SOURCE Purdue Pharma L.P.